{
    "2021-02-07": [
        [
            {
                "time": "",
                "original_text": "医药生物行业周报：新冠变异后是否需要常态化免疫加强？智飞新高后继续强烈看好",
                "features": {
                    "keywords": [
                        "医药生物",
                        "新冠变异",
                        "常态化免疫",
                        "智飞",
                        "新高",
                        "强烈看好"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "大参林医药集团股份有限公司第一百一十分店 其他违规处罚",
                "features": {
                    "keywords": [
                        "大参林",
                        "医药集团",
                        "违规处罚"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药零售"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}